Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

This study tests a combination of three drugs — olverembatinib, venetoclax, and dexamethasone — in patients newly diagnosed with a specific form of leukemia called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This combination targets multiple pathways to try to achieve remission without requiring intensive chemotherapy. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Ph+ acute lymphoblastic leukemia (a type of fast-growing blood cancer) - Your liver, kidneys, and heart are functioning adequately - Your expected survival is more than 3 months - You are willing to use contraception and meet pregnancy testing requirements **You may NOT be eligible if...** - You are currently enrolled in another clinical trial - You are pregnant or breastfeeding - You have had major surgery within the past 3 weeks - You have an active infection requiring IV medications - You have HIV or active hepatitis infection - You have severe lung disease (COPD with very low breathing function) - You have difficulty swallowing or absorbing oral medications Talk to your doctor to see if this trial is right for you.